Developing alerting thresholds for prospective drug safety monitoring

Current methods for prospective drug safety monitoring focus on determining whether and when to generate safety alerts indicating that a new drug may be less safe than a comparator. Approaches are needed to develop safety thresholds that can be used to define whether a new drug is no less than or equally safe as the comparator.

[1]  Mark Levenson,et al.  Cardiovascular, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated With Dabigatran or Warfarin for Nonvalvular Atrial Fibrillation , 2015, Circulation.

[2]  J. Rassen,et al.  A modular, prospective, semi‐automated drug safety monitoring system for use in a distributed data environment , 2014, Pharmacoepidemiology and drug safety.

[3]  Jun Liu,et al.  Near-Real-Time Monitoring of New Drugs: An Application Comparing Prasugrel Versus Clopidogrel , 2014, Drug Safety.

[4]  J. Gagne,et al.  Interpreting the quality of health care database studies on the comparative effectiveness of oral anticoagulants in routine care , 2013 .

[5]  G. Lip,et al.  Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study. , 2013, Journal of the American College of Cardiology.

[6]  L. Køber,et al.  Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study , 2013, BMJ Open.

[7]  Marsha E Reichman,et al.  Dabigatran and postmarketing reports of bleeding. , 2013, The New England journal of medicine.

[8]  E. Vermetten,et al.  Police officers: a high-risk group for the development of mental health disturbances? A cohort study , 2013, BMJ Open.

[9]  Preciosa M. ColomaGianluca Trifiro.  Where does Signal Detection Using Electronic Healthcare Records Fit into the Big Picture , 2013 .

[10]  V. Lee,et al.  Dabigatran Compared With Warfarin for Stroke Prevention With Atrial Fibrillation: Experience in Hong Kong , 2012, Clinical cardiology.

[11]  Jeremy A Rassen,et al.  An Event‐Based Approach for Comparing the Performance of Methods for Prospective Medical Product Monitoring , 2012, Pharmacoepidemiology and drug safety.

[12]  Sebastian Schneeweiss,et al.  Active safety monitoring of newly marketed medications in a distributed data network: application of a semi-automated monitoring system , 2012, Clinical pharmacology and therapy.

[13]  Jeremy A Rassen,et al.  Active Safety Monitoring of New Medical Products Using Electronic Healthcare Data: Selecting Alerting Rules , 2012, Epidemiology.

[14]  Richard Platt,et al.  The U.S. Food and Drug Administration's Mini‐Sentinel program: status and direction , 2012, Pharmacoepidemiology and drug safety.

[15]  Arno W. Hoes,et al.  Room for Improvement in Conducting and Reporting Non-Inferiority Randomized Controlled Trials on Drugs: A Systematic Review , 2010, PloS one.

[16]  A. Hoes,et al.  Interpretation and Inference in Noninferiority Randomized Controlled Trials in Drug Research , 2010, Clinical pharmacology and therapeutics.

[17]  S. Yusuf,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[18]  Diem-Kieu H. Ngo.  FOOD AND DRUG ADMINISTRATION (FDA) Center for Drug Evaluation and Research (CDER) , 2008 .

[19]  C H Schmid,et al.  Cumulative meta-analysis of clinical trials builds evidence for exemplary medical care. , 1995, Journal of clinical epidemiology.

[20]  Leandro Provinciali,et al.  Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke , 1993 .

[21]  D. Singer,et al.  The effect of aspirin on the risk of stroke in patients with nonrheumatic atrial fibrillation: The BAATAF Study. , 1992, American heart journal.

[22]  S M Nazarian,et al.  Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. , 1992, The New England journal of medicine.

[23]  M Gent,et al.  Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. , 1991, Journal of the American College of Cardiology.

[24]  Lippincott Williams Wilkins,et al.  Stroke Prevention in Atrial Fibrillation Study: Final Results , 1991, Circulation.

[25]  Palle Petersen,et al.  PLACEBO-CONTROLLED, RANDOMISED TRIAL OF WARFARIN AND ASPIRIN FOR PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN CHRONIC ATRIAL FIBRILLATION The Copenhagen AFASAK Study , 1989, The Lancet.